|Bid||57.75 x 800|
|Ask||57.78 x 1100|
|Day's Range||57.75 - 59.59|
|52 Week Range||29.01 - 59.76|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||28.37|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.67|
Zacks.com featured highlights include: KB Home, Crocs, NetEase, Taylor Morrison Home and Anika Therapeutics
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Anika Therapeutics, Inc. (ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform, today announced plans to showcase its osteoarthritis pain management and joint preservation and restoration regenerative therapies at the Annual Scientific Meeting of the International Society for Hip Arthroscopy (ISHA). The ISHA Annual Scientific Meeting is being held October 17-19, 2019 in Madrid, Spain, and it provides a unique international forum for attendees to share scientific information and learn the latest advancements of arthroscopic surgery of the hip.
Industry veteran brings extensive experience leading global regulatory, quality, and clinical affairs teams
Anika Therapeutics, Inc. today announced that the Company plans to issue its third-quarter 2019 financial results after the close of the market on Thursday, October 24, 2019 and hold its investor conference call on the same day, Thursday, October 24, 2019, at 5:00 p.m.
Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Anika Therapeutics, Inc. , a global, integrated regenerative therapies company leveraging its proprietary hyaluronic acid technology platform, today announced plans to showcase its osteoarthritis pain management and joint preservation and restoration therapies at the 15th World Congress of the International Cartilage Regeneration and Joint Preservation Society .
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. At its hardware event, (AMZN) [ticker: AMZN] announced the launch of its Sidewalk network, which we believe is based on [Semtech’s] LoRa [technology]. Sidewalk is Amazon’s new low-bandwidth network that uses the 900 megahertz spectrum, roughly the same spectrum range as LoRa.
Anika (ANIK) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Avid Bioservices (CDMO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid ("HA") technology platform to provide therapies across the Joint Preservation and Restoration continuum of care, today announced it has commenced the U.S. commercial soft launch of TACTOSET, its injectable HA-enhanced bone repair therapy. TACTOSET has been developed for the treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. TACTOSET is Anika’s first product to launch under its U.S.-based hybrid commercial model.
Anika Therapeutics, Inc. , a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will host an Analyst and Investor Day on Wednesday, September 18, 2019 from 9:00 a.m.
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that Joseph Darling, President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat at the 2019 Morgan Stanley Global Healthcare Conference on Tuesday, September ...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Anika Therapeutics received an upgrade to 'Buy' on Monday from TheStreet.com's quantitative service which comes on the heels of its technical breakout last week. In this daily bar chart of ANIK, below, we can see a year-long base pattern with an upside gap/breakout. The On-Balance-Volume (OBV) line turned up to a new high to confirm the buying and so did the Moving Average Convergence Divergence (MACD) oscillator.
Here are four stocks to watch, three of which are moving on strong earnings reports. Anika Therapeutics Inc. (ANIK) popped $11.78, or 29%, to $52.60 on Thursday on 1.3 million shares traded, or about eight times its average volume. The breakaway gap, and continued runup, broke the stock through several layers of lateral resistance, with the next target at the $61 level last reached in early 2018.
Here are four stocks to watch, three of them moving on strong earnings: Anika Therapeutics, Inc . (NASDAQ: ANIK ) popped $11.78, or 28.8%, to $52.60 on Thursday on 1.3 million shares, or about 8x its average ...